Equities

BioRestorative Therapies Inc

BioRestorative Therapies Inc

Actions
FinancialsInvestment Banking and Brokerage Services
  • Price (USD)1.47
  • Today's Change0.025 / 1.73%
  • Shares traded33.09k
  • 1 Year change-20.97%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for BioRestorative Therapies Inc have a median target of 13.00, with a high estimate of 18.00 and a low estimate of 8.00. The median estimate represents a 799.65% increase from the last price of 1.45.
High1,145.7%18.00
Med799.7%13.00
Low453.6%8.00

Earnings history & estimates in USD

On Nov 12, 2024, BioRestorative Therapies Inc reported 3rd quarter 2024 losses of -0.134 per share. This result exceeded the -0.43 consensus loss of the 2 analysts covering the company and exceeded last year's 3rd quarter results by 79.38%.
The next earnings announcement is expected on Mar 28, 2025.
Average growth rate+19.02%
BioRestorative Therapies Inc reported annual 2023 losses of -3.42 per share on Apr 01, 2024.
Average growth rate+59.69%
More ▼

Revenue history & estimates in USD

BioRestorative Therapies, Inc. had 3rd quarter 2024 revenues of 464.00k. This bettered the 350.00k consensus of the 2 analysts covering the company. This was 1,396.77% above the prior year's 3rd quarter results.
Average growth rate+155.28%
BioRestorative Therapies, Inc. had revenues for the full year 2023 of 146.00k. This was 21.67% above the prior year's results.
Average growth rate+91.27%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.